RJW103
Based on 1 Customer Validation
RJW103 is an acid-stable SF-1 (NR5A1) and LRH-1 agonist with pEC50 values of 6.5 and 5.9, respectively. RJW103 activates SF-1- and LRH-1-mediated transcription of endogenous target genes. RJW103 can be used in research on cancer, endocrinology and metabolic diseases, such as adrenocortical tumors.
For research use only. We do not sell to patients.
- Purity: 98.71%
- CAS No.: 1276664-14-2
- Formula: C28H35N
- Molecular Weight:385.58
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Transcription Factor-Targeted Library
HY-L090
-
Nuclear Receptor Compound Library
HY-L126
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
SF-1 (NR5A1) 6.5 (pEC50) |
LRH-1 5.9 (pEC50) |
RJW103 (10 μM; 24 h) activates SF-1-mediated transcription of SHP, StAR, G0S2, and MeOX1 in mSF-1-expressing HEK293 cells, and activates LRH-1-mediated transcription of StAR and G0S2 (but not SHP or MeOX1) in hLRH-1-expressing HEK293 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293 cells stably expressing mouse SF-1, HEK293 cells stably expressing human LRH-1
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly increased mRNA levels of the endogenous target genes SHP, StAR, G0S2, and MeOX1 in mSF-1-expressing HEK293 cells.
Significantly increased mRNA levels of StAR and G0S2, but did not activate SHP or MeOX1 in hLRH-1-expressing HEK293 cells.
Chemical Information
-
CAS No. 1276664-14-2
-
Appearance Oil
-
Molecular Weight 385.58
-
Formula C28H35N
-
Color Light yellow to yellow
-
SMILES
C=C([C@]1(C(C2=CC=CC=C2)=C(CCCCCC)C3)[C@]3([H])CN(C)C1)C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (259.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.48 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Whitby RJ, et al. Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2). J Med Chem. 2011;54(7):2266-2281. [Content Brief]
[2]. Wu T, et al. Liver receptor homolog-1: structures, related diseases, and drug discovery. Acta Pharmacol Sin. 2024;45(8):1571-1581. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5935 mL | 12.9675 mL | 25.9350 mL | 64.8374 mL |
| 5 mM | 0.5187 mL | 2.5935 mL | 5.1870 mL | 12.9675 mL | |
| 10 mM | 0.2593 mL | 1.2967 mL | 2.5935 mL | 6.4837 mL | |
| 15 mM | 0.1729 mL | 0.8645 mL | 1.7290 mL | 4.3225 mL | |
| 20 mM | 0.1297 mL | 0.6484 mL | 1.2967 mL | 3.2419 mL | |
| 25 mM | 0.1037 mL | 0.5187 mL | 1.0374 mL | 2.5935 mL | |
| 30 mM | 0.0864 mL | 0.4322 mL | 0.8645 mL | 2.1612 mL | |
| 40 mM | 0.0648 mL | 0.3242 mL | 0.6484 mL | 1.6209 mL | |
| 50 mM | 0.0519 mL | 0.2593 mL | 0.5187 mL | 1.2967 mL | |
| 60 mM | 0.0432 mL | 0.2161 mL | 0.4322 mL | 1.0806 mL | |
| 80 mM | 0.0324 mL | 0.1621 mL | 0.3242 mL | 0.8105 mL | |
| 100 mM | 0.0259 mL | 0.1297 mL | 0.2593 mL | 0.6484 mL |
Powered by Bioz